OCUL · Ocular Therapeutix, Inc · Executive Compensation
$5.99
+0.05 (+0.84%)
At close · Nov 19
Return incl. dividend (before tax)
Play latest call
Q3 2026 earnings call transcript
Market Cap
$1.31B
Shares
220.02M
Volume · Nov 19
205.83K
Avg daily vol (3M)
3.04M
You came from your AI assistant. Add Equibles to it and ask about this data directly, free.
Named-executive compensation from the company's DEF 14A proxy statements — salary, bonus, stock and option awards, non-equity incentive, and the company-reported total per executive per fiscal year, exactly as disclosed in the Summary Compensation Table.
No Compensation Data
No Summary Compensation Table has been imported from this company's proxy statements yet.
Executive changes
| Person | Role | Change | Filed |
|---|---|---|---|
|
Seung Suh Hong, Ph.D.
“Dr. Hong’s resignation is not the result of any disagreement with the Board or with management on any matter relating to the Company’s operations, policies or practices.”
|
member of the Board | Resigned | 2026-11-09 |
| Riad Sherif, M.D. | member of the Board | Appointed | 2026-11-09 |
| Sanjay Nayak, M.B.B.S., Ph.D. | Chief Strategy Officer | Resigned | 2026-10-16 |
| Jason Robins | Chief Financial Officer | Appointed | 2026-06-12 |
| Jason Robins | interim Chief Financial Officer | Appointed | 2026-01-23 |
| Leslie J. Williams | Class II director | Appointed | 2025-06-11 |
| Richard L. Lindstrom, M.D. | Class II director | Appointed | 2025-06-11 |
| Seung Suh Hong, Ph.D. | Class II director | Appointed | 2025-06-11 |
| Donald Notman | Chief Operating Officer | Appointed | 2024-09-03 |
| Charles Warden | Class I director | Appointed | 2024-06-14 |
| Adrienne L. Graves, Ph.D. | Class I director | Appointed | 2024-06-14 |
| Rabia Gurses Ozden, M.D. | Chief Medical Officer | Resigned | 2024-04-18 |
| Nadia Waheed, M.D. | Chief Medical Officer | Appointed | 2024-04-18 |
|
Antony C. Mattessich
“Mr. Mattessich's resignation was not the result of any disagreement with the Company on any matter relating to its operations, policies or practices.”
|
director | Resigned | 2024-04-18 |
| Pravin U. Dugel, M.D. | President and Chief Executive Officer | Appointed | 2024-04-18 |
| Peter Kaiser | Medical Director | Appointed | 2024-02-22 |
| Sanjay Nayak | Chief Strategy Officer | Appointed | 2024-02-22 |
| Jeffrey S. Heier | Chief Scientific Officer | Appointed | 2024-02-22 |
|
Jeffrey S. Heier
“At the time of his resignation, Dr. Heier informed the Company that his resignation was not based upon any disagreement with the Board, or with the management of the Company, on any matter relating to the Company’s operations, policies or practices.”
|
Board | Resigned | 2024-02-22 |
| Pravin U. Dugel | Class III director | Appointed | 2024-02-22 |
| Pravin U. Dugel | Executive Chairman | Appointed | 2024-02-22 |
| Adrienne L. Graves, Ph.D. | member of the Board | Appointed | 2023-07-12 |
| Merilee Raines | Class III director | Appointed | 2023-06-16 |
| Jeffrey S. Heier, M.D. | Class III director | Appointed | 2023-06-16 |
| Leslie J. Williams | Class II director | Appointed | 2022-06-17 |
Leadership
- Pravin Dugel CEO
- Pravin U. Dugel CEO, Chairman, Board Member
- Pravin U. Dugel, M.D. CEO, Chairman
- Charles Warden Chairman, Board Member
- Jason Robins CFO
- Donald Notman COO
- Philip C. Strassburger General Counsel
- Adrienne L. Graves Board Member
- Adrienne L. Graves, Ph.D. Board Member
- Jeffrey Heier Board Member
- Jeffrey S. Heier, M.D. Board Member
- Leslie J. Williams Board Member
- Merilee Raines Board Member
- Riad Sherif, M.D. Board Member
- Richard L. Lindstrom Board Member
- Richard L. Lindstrom, M.D. Board Member
- Seung Suh Hong Board Member
- Seung Suh Hong, Ph.D. Board Member
Key facts
CIK
1393434
CUSIP
67576A100
13F (30d)
269 filings
250 filers
Visit website
Investor relations